Wanbury Ltd: USFDA Inspection Concludes with Six Observations
Wanbury Ltd has announced the completion of a routine USFDA inspection at its Tanuku facility, conducted from July 13-17, 2026. The inspection resulted in six observations documented on a Form 483. The company stated that these observations are addressable and does not anticipate any material impact on its manufacturing operations, exports, or financial performance. Wanbury Ltd will submit its response to the FDA within the stipulated timeframe and will provide further updates as necessary.
Key Highlights
- USFDA inspection completed at Wanbury's Tanuku facility.
- Six observations were issued on Form 483 post-inspection.
- Company expects no material impact on operations or financials.
- Wanbury Ltd will respond to observations within the stipulated time.
Price Impact
More from WANBURY
More in USFDA
Jeevan Scientific Technology Completes USFDA Inspection With No Observations
Glenmark Pharma's RYALTRIS Nasal Spray Approved for Children 6-12 by US FDA
Alembic Pharma Partner Natco Pharma Gets USFDA Tentative Approval for Olaparib Tablets